I would add, if this does not slow wound healing but rather hastens due to reduced microbial flora in the wound bed and wound healing has reduced hypergranulation, we are on a major winner. Infection/high bioburden are leading causes of poor wound healing and hypergranulation.
If these endpoints are met, I see the share price reaching into the $3-4 quickly. The market cap is only $172m and will deserve a higher price.
The one caveat is this is a phase 1 trial that is only about tolerability and safety and so the endpoints above may not be revealed yet.
RCE Price at posting:
99.5¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)